An investigation on behalf of investors in OTCMKTS:HPPI shares over potential wrongdoing at HedgePath Pharmaceuticals Inc was announced and OTCMKTS:HPPI stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/31/2017 -- An investigation on behalf of current long-term investors in shares of HedgePath Pharmaceuticals Inc (OTCMKTS:HPPI) was announced over potential breaches of fiduciary duties by certain directors at HedgePath Pharmaceuticals Inc.
Investors who purchased shares of HedgePath Pharmaceuticals Inc (OTCMKTS:HPPI) and currently hold any of those OTCMKTS:HPPI shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain HedgePath Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Tampa, FL based HedgePath Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical that is focused on discovering, developing and commercializing therapeutics for patients with certain cancers.
Shares of HedgePath Pharmaceuticals Inc (OTCMKTS:HPPI) declined from $0.47 per share in August 2016 to as low as $0.24 per share on March 22, 2017.
On March 30, 2017, OTCMKTS:HPPI shares closed at $0.26 per share.
Those who purchased shares of HedgePath Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com